ArticleCellular oncology (Dordrecht, Netherlands)2026
ACTG1 promotes breast cancer aggressiveness and confers ribociclib resistance by deubiquitinating HSPA8 through UCHL3.
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we examined the biological significance of the actin gamma 1 (ACTG1)-UCHL3–HSPA8 axis in breast cancer. Through bioinformatic analysis, we recognized ACTG1 as a potential oncogenic factor in BRCA. By exploiting qRT-qPCR and Western blot analysis, we assessed the expression of ACTG1 and explored its impact on cellular proliferation, migration, and invasion. Our findings suggest that ACTG1 exerts its oncogenic effects in breast cancer cells through the EMT signaling pathway. By mining the BIOGRID database, we identified potential downstream regulatory genes; and co-immunoprecipitation assays confirmed protein interactions between ACTG1 and HSPA8. We also observed that ACTG1 promoted breast cancer cell proliferation, invasion, and migration via its interaction with HSPA8. Importantly, our study elucidated the facilitation by UCHL3 of HSPA8 deubiquitination by ACTG1. In conclusion, our study revealed a key role played by the ACTG1–UCHL3–HSPA8 axis in driving breast cancer progression as well as the role of ribociclib resistance. Our findings provide compelling evidence for the therapeutic potential of targeting this axis in breast cancer treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.